Scancell Holdings (AIM: SCLP) Strikes Exclusive Evaluation Deal with Major Biotech Firm

Scancell Holdings plc (AIM: SCLP), a pioneer in the realm of oncology immunotherapies, has made waves once again with a significant announcement. The company revealed today that a major international biotechnology firm will exclusively evaluate one of Scancell's investigational anti-glycan monoclonal antibodies for the development of novel therapeutic products.

Under the terms of this agreement, Scancell has granted the biotech giant a seven-month exclusivity period for the evaluation process. As part of the deal, the company will make an impressive $1 million exclusivity payment within 30 days, affirming the value and potential of Scancell's antibody technology.

Professor Lindy Durrant, Chief Executive Officer of Scancell, expressed her satisfaction with the partnership, stating, "We are very pleased to announce this agreement today with a leading international biotechnology company." She emphasized the significance of this collaboration, highlighting that it marks the second anti-glycan monoclonal antibody from Scancell's proprietary GlyMab® platform to undergo evaluation for therapeutic development. This achievement further validates the capability of Scancell's antibody platform to generate novel and differentiated antibody products, signaling promising prospects for future advancements in cancer treatment.

The Scancell anti-glycan monoclonal antibody, a humanized antibody crafted through the innovative GlyMab® platform, represents a breakthrough in cancer therapy. This antibody is among the five monoclonal antibodies currently within Scancell's antibody portfolio, showcasing the company's commitment to pioneering research and development in oncology.

At the core of Scancell's innovative approach lies GlyMab®, a groundbreaking technology that targets sugar motifs rather than proteins in cancer cells. The company's unique methodology has led to the development of five novel monoclonal antibodies in early-stage development, with the potential for more discoveries in the future. By targeting glycans, which undergo alterations during the transition from normal to cancerous cells, Scancell's GlyMab® portfolio holds immense promise in revolutionizing cancer treatment.

Scancell's GlyMab® platform is supported by a robust portfolio of patents and applications, underscoring the company's leadership in the field of immunotherapy. Moreover, Scancell's antibody portfolio includes AvidiMab®, another cutting-edge technology that enhances the potency and efficacy of antibodies in killing tumor cells.